DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization

DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization

Item

http://www.wikidata.org/entity/Q33773787

Q33773787

about

Vaccine adjuvants as potential cancer immunotherapeutics Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches Modulation of the tumor microenvironment for cancer treatment: a biomaterials approach Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach Patterns of Vasculature in Mouse Models of Lung Cancer Are Dependent on Location.Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors.Cutting Edge: Novel Tmem173 Allele Reveals Importance of STING N Terminus in Trafficking and Type I IFN Production.Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.The host STING pathway at the interface of cancer and immunity Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways STING, nanoparticles, autoimmune disease and cancer: a novel paradigm for immunotherapy?Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy.An RNA-Based Fluorescent Biosensor for High-Throughput Analysis of the cGAS-cGAMP-STING Pathway.Cyclic GMP-AMP Ameliorates Diet-induced Metabolic Dysregulation and Regulates Proinflammatory Responses Distinctly from STING Activation.The Expression and Relationship of CD68-Tumor-Associated Macrophages and Microvascular Density With the Prognosis of Patients With Laryngeal Squamous Cell Carcinoma.The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression.Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade.A positive-feedback loop between tumour infiltrating activated Treg cells and type 2-skewed macrophages is essential for progression of laryngeal squamous cell carcinoma.PTD modified paclitaxel anti-resistant liposomes for treatment of drug-resistant non-small cell lung cancer.A High Content Screen in Macrophages Identifies Small Molecule Modulators of STING-IRF3 and NFkB Signaling.Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors.Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy Combination therapy of simvastatin and 5, 6-dimethylxanthenone-4-acetic acid synergistically suppresses the aggressiveness of B16.F10 melanoma cells

P2860

Q26752522-41F555F3-BFDB-492C-AC77-49679EE8EF36 Q26774312-A232E1BB-8D61-4CF8-9EE4-265C36B885D9 Q26996790-D0F1D2CE-68C8-4C87-9E8B-B08E2F39C3EB Q28388409-830C6618-3444-41EA-A63D-085CF966D493 Q36154645-9CD45692-E649-4C8F-8986-F54B55327184 Q36436992-F504A071-EF01-409E-883A-F756C8FBC291 Q36447597-CB42C596-6CD3-445A-A10A-C8FD5D4BD54E Q37017190-0CC3402D-1265-4D9A-828B-A9565BCD7DC2 Q37042237-F0FE12BC-368B-46DE-B5E3-23DB2AEA76BD Q37690959-7C740BFA-266E-4B37-8278-F3878615DA23 Q38293111-59FBB167-3A2A-4EA8-8D1C-AA03F4317D5C Q39280710-D6D3EADB-204E-43A0-997C-D92570C53306 Q40434927-731E3D1B-DD07-4EC6-ABB0-1B284927EA6E Q41124118-1AD1AE70-E83D-401C-9DB3-085EE2D5193D Q41284044-8C86D444-7124-4F4B-BD1C-8CB19BF0B334 Q46142906-7431A220-A510-4C71-AD11-1037A9B18CDD Q46189367-0235683A-00A1-433D-9457-4DF916F12625 Q47122380-297A29F8-F8BC-421C-9BED-7FEBA4A1E5F2 Q47391699-192BE485-DEA2-4191-B97B-934E9CB5B5DD Q49823387-1CDD87A7-4835-43CC-ADB1-FBC57D51AD07 Q50646630-52662DFB-CFE2-42CB-9B44-8A9F29D198B7 Q52649165-79B6915D-BF8D-4F6C-8040-6AE958B179EB Q55020612-ABD13B59-AC80-46FE-B57D-B69F43CBB81E Q57817490-F8AD025B-906E-41F2-8EF7-CF1D2E0C45A0 Q58714990-CB42B908-89AF-41B2-9B12-F3C38C94498F

P2860

DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization

Item

http://www.wikidata.org/entity/Q33773787

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu